Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Location
320 West 37 Th Street, New York, NY
State of incorporation
DE
Fiscal year end
March 31
Former names
Health Sciences Acquisitions Corp (to 12/20/2019)
Latest financial report
10-Q - Q4 2024 - Feb 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 951 % -9.53%
Debt-to-equity 11.6 % +11%
Return On Equity -77.9 % -27.5%
Return On Assets -69.8 % -26.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 170M shares +16.9%
Common Stock, Shares, Outstanding 147M shares +1.45%
Entity Public Float 2.18B USD +811%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 147M shares +1.66%
Weighted Average Number of Shares Outstanding, Diluted 147M shares +1.66%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 71.9M USD +31%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -382M USD -56.6%
Income Tax Expense (Benefit) 539K USD
Net Income (Loss) Attributable to Parent -383M USD -57.2%
Earnings Per Share, Basic -2.6 USD/shares -41.3%
Earnings Per Share, Diluted -2.6 USD/shares -41.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 375M USD -45.8%
Accounts Receivable, after Allowance for Credit Loss, Current 2.22M USD +116%
Assets, Current 413M USD -42%
Property, Plant and Equipment, Net 752K USD +100%
Operating Lease, Right-of-Use Asset 22K USD -92.5%
Other Assets, Noncurrent 7.62M USD
Assets 421M USD -40.8%
Accounts Payable, Current 19.8M USD +407%
Accrued Liabilities, Current 48.5M USD +73.8%
Liabilities, Current 68.3M USD +113%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 68.3M USD +113%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.48M USD
Retained Earnings (Accumulated Deficit) -1.13B USD -51%
Stockholders' Equity Attributable to Parent 353M USD -48.1%
Liabilities and Equity 421M USD -40.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -76.2M USD -60.9%
Net Cash Provided by (Used in) Financing Activities 686K USD -22.9%
Net Cash Provided by (Used in) Investing Activities -182K USD -304%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 147M shares +1.45%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -75.4M USD -61.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 375M USD -45.8%
Deferred Tax Assets, Valuation Allowance 141M USD +53.8%
Deferred Tax Assets, Gross 142M USD +53.3%
Operating Lease, Liability 138K USD -88.7%
Depreciation 80K USD +50.9%
Payments to Acquire Property, Plant, and Equipment 182K USD +304%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -380M USD -55.4%
Lessee, Operating Lease, Liability, to be Paid 141K USD -88.7%
Operating Lease, Liability, Current 23K USD -92.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 47K USD -96.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -88.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -88%
Deferred Tax Assets, Operating Loss Carryforwards 98.2M USD +52.5%
Preferred Stock, Shares Issued 0 shares
Additional Paid in Capital 1.48B USD +3.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 347K USD -30.9%
Share-based Payment Arrangement, Expense 47.4M USD +22.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%